EXPERIENCE OF TESTICULAR CANCER PATIENT LONG TERM FOLLOW-UP IN TERTIARY REFERRAL HOSPITAL
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
Abstract
Objective: This study aims to determine the survivability testicular cancer patients at a tertiary hospital in Malang, Indonesia. Material & Methods: This is study conducted from January 2021 to January 2022 at Saiful Anwar General Hospital in Malang, East Java. Involving 32 testicular cancer patients. Data was obtained through medical record January 2017 – January 2022. Analysis was carried out to determine the survivability of the patient. Results: The results showed that the proportion of 1 to 5 year survival rate in testicular cancer patients was 96% and 21%. Kaplan Meier test showed significant difference of patient survival in the radiation therapy exposure (p=0.021), Karnofsky score (p=0.010), tumour type (p=0.019), and response of chemotherapy (p=0.015). Conclusion: The survival rate of testicular cancer patients are strongly influenced by the karnofsky score, radiation therapy exposure, tumour type, and chemotherapy response. Therefore early diagnosis and treatment plays an important role in improving survival rate of the patients. Keywords: Testicular cancer, survival rate, seminoma, non seminoma.
##plugins.themes.bootstrap3.article.details##
Testicular cancer, survival rate, seminoma, non seminoma
Cheng L, Albers P, Berney DM, et al. Testicular cancer. Nat Rev Dis Prim. 2018; 4.
Garner MJ, Turner MC, Ghadirian P, et al. Epidemiology of testicular cancer: An overview. Int J Cancer. 2005; 116: 331–9.
Oldenburg J, Fosså SD, Nuver J, et al. Testicular seminoma and non-seminoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24: vi125–32.
Moch H, Cubilla AL, Humphrey PA, et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours. Eur Urol. 2016; 70: 93–105.
Kishore J, Goel M, Khanna P. Understanding survival analysis: Kaplan-Meier estimate. Int J Ayurveda Res. 2010; 1: 274.
Derouen MC, Mujahid M, Srinivas S, et al. Disparities in Adolescent and Young Adult Survival after Testicular Cancer Vary by Histologic Subtype: A Population-Based Study in California 1988-2010. J Adolesc Young Adult Oncol. 2016; 5: 31–40.
Dong W, Gang W, Liu M, et al. Analysis of the prognosis of patients with testicular seminoma. Oncol Lett. 2016; 11: 1361–6.
Verhoeven RHA, Gondos A, Janssen-heijnen MLG, et al. Testicular cancer in Europe and the USA: Survival still rising among older patients. Ann Oncol. 2013; 24: 508–13.
Daugaard G, Gundgaard MG, Mortensen MS, et al. Surveillance for stage I nonseminoma testicular cancer: Outcomes and long-term follow-up in a population-based cohort. J Clin Oncol. 2014; 32: 3817–23.
Verhoeven RHA, Karim-Kos HE, Coebergh JWW, et al. Markedly increased incidence and improved survival of testicular cancer in the Netherlands. Acta Oncol (Madr). 2014; 53: 342–50.
Kamel MH, Elfaramawi M, Jadhav S, et al. Insurance Status and Differences in Treatment and Survival of Testicular Cancer Patients. Urology. 2016; 87: 140–5.
Jang RW, Caraiscos VB, Swami N, et al. Simple prognostic model for patients with advanced cancer based on performance status. J Oncol Pract. 2014; 10: e335–41.
Hwang SS, Scott CB, Chang VT, et al. Prediction of survival for advanced cancer patients by recursive partitioning analysis: Role of karnofsky performance status, quality of life, and symptom distress. Cancer Invest. 2004; 22: 678–87.
Kwok S, Pang J, Salvo N, et al. Prognostic assessment of the cancer patient [Internet]. Supportive Oncology. Elsevier Inc.; 2011. 472–484 p.
Robinson D, Møller H, Horwich A. Mortality and incidence of second cancers following treatment for testicular cancer. Br J Cancer. 2007.